drugset / Trial / NCT00455975
High-dose Bevacizumab in Advanced Renal Carcinoma Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This trial will examine the effectiveness and the side effects of 2 higher dosing schedules of bevacizumab in patients that have advanced clear cell renal carcinoma.
Timeline
- Start
- 2007-02
- Primary completion
- 2013-07
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |